


November 2012







- The Public's Health
- Ageing / Dementia
- Non-communicable Diseases
- Infections
- Rare Diseases
- Our R&D response





• The Public's Health



Alcohol – a public health problem



- Alcohol ranks as the third highest behavioural risk factor for disease and death in the UK, and is linked to liver disease, diabetes, CVD, and some cancers, as well as violent crime
- ➤ The costs of alcohol to the NHS are estimated at £3.5bn per year
- ➤ Lost productivity due to alcohol across the UK is estimated at £7.3 billion a year (2009/10 costs)



7

Liver Disease DH Department of Health **ALCOHOL:** Average annual mortality The future due to liver disease by upper tier local authority, England, 2008-10 Standardised liver death rate (per 100,000) France EU mean UK Netherlands Norway 1990 2030 Year

Investing in alcohol research for policy and practice improvement



- Testing the public acceptability of population-level interventions to reduce alcohol consumption – for example, alcohol minimum unit pricing
- ➤ Estimating the short-term impact on alcohol purchasing of a ban on multi-buy promotions
- > Estimating the impact of changes in alcohol strength and glass size on statistics on trends in alcohol consumption in England
- Developing an evidence-based model for estimating requirements for specialist alcohol treatment capacity
- Developing and evaluating interventions for adolescent alcohol use disorders presenting through emergency departments
- ➤ Evaluating the effectiveness of screening and brief alcohol intervention in primary care (SIPS trial)

9

Obesity - key messages




- · One in four adults are obese
- More than 60% are overweight or obese
- Patterns broadly similar for men and women
- 1 million adults are morbidly obese (BMI of 40 or more)

Obesity - our future



Projected prevalence of overweight in eight countries



Wang YC et al (2011). Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378:815-25.

Examples of the R&D Response



Policy Research Units on (i) Behaviour and Health; (ii) Public Health Research Consortium

NIHR HTA Disease Prevention Panel and Public Health Research Programme

Partnership with other funders on (i) National Prevention Research Initiative, (ii) UKCRC PH Research Centres of Excellence

NIHR School for Public Health Research

Extensive involvement in primary research, secondary analysis and evidence synthesis to support policy evaluation.


• Ageing / Dementia




Annual Report of the Chief Medical Officer, Volume 1, 2011 Population England, 2010, 2020 304 35-59 45-69 4

Dementia


- Worldwide nearly 36 million people live with dementia
 - Expected to almost double by 2030 (66 million) and more than triple by 2050 (115 million)
 - In England 670,000 people live with dementia
- · Global expenditure estimates on dementia-





• Non-communicable Diseases





NHS National Institute for Health Research

Infrastructure

Clinical Research Networks


Clinical Research Facilities, Centres & Units "...the support and facilities the NHS needs for first class research..."

Recruitment to Cancer studies in 2011/12 - England

87,806 participants in total recruited into the NIHR-portfolio of cancer studies in England

52,975 cancer (& pre-malignant) patients in England (**22.9%** of incident cases)


More than a **5 fold** increase from 2001



Genomic Technologies: anticipating risk in the short, medium and long term



- •Potential of Genomics, in the form of whole genome and exome sequencing, to transform healthcare;
- •Unique position of the NHS as a single, national healthcare provider;
- •Wealth creating possibilities




What we are doing



- Government initiative to sequence 100,000 whole genomes from NHS patients
- · Initial focus on cancer, rare disease and infectious disease
- Programme will deliver a platform of genome data linked to diagnosis and outcomes for research and commercial application
- DH earmarked up to £100million funding to pump-prime sequencing; provide a trained workforce and support commercial applications
- CMO to oversee the programme to ensure patient interests are protected. Three expert groups (Science, Data and Ethics) to advise her by April 2013
- NHSCB Genomics Strategy Board, chaired by Malcolm Grant, to develop NHS implementation strategy, including sequencing capacity and preparing the workforce
- Programme to go live in April 2014

Issues for Discussion

Infections



Pandemic Influenza



The National Risk Assessment recognises pandemic influenza as one of the highest risks for the UK.

Pandemic preparedness planning focuses on:

- reducing the spread
- reducing illness and complications
- reducing deaths
- reducing infection



The UK is recognised by the WHO as being one of the best prepared countries.

Pandemic Influenza Research



- 9 "sleeping contracts" have been let by NIHR HTA Programme HPA
- Proposals funded and initial study preparatory work done, so studies can be started quickly when required
- Includes studies on epidemiology and modelling; communication with the public; real time refinement of criteria/tools used for hospital referrals from primary care; triage in the emergency department; early estimation of antiviral and vaccine effectiveness
- DH PRP is considering proposal for behavioural aspects of flu pandemic and has call for 'alternative opinion' modelling capacity for pandemic (and seasonal) flu.

Antimicrobial Resistance



- Rising Resistance;
- Market Failure;
- Rapid worldwide spread of multidrug-resistant (MDR) bacteria;

Action:


- · CMO Annual Report on infection, and
- A cross UK government five year AMR strategy

AMR / HCAI - Research



- NIHR/DH
 - Major contributor to UKCRC Translational Infections Research Initiative 2008-2016 (other major funders are Wellcome and MRC) which funds 4 consortia
 - Contributes £5m to TSB Innovation Platform on detection and identification of infectious diseases
 - Programmes of research (c £9m in 2012) in NIHR Biomedical Research Centres
 - Numerous projects funded through other programmes including the HTA and the DH Policy Research Programme


Rare Diseases




Rare Diseases




- Setting up NIHR Rare Diseases Translational Research Collaboration
 - 'deep' phenotyping
 - NIHR Biomedical Research Centres, Biomedical Research Units, Clinical Research Facilities
- NIHR Themed call for research into **very rare** diseases (affecting less than 1 in 100,000 of the general population)
 - six NIHR-managed research programmes
 - research on rare diseases (EU definition of 5 in 10,000) as part of the normal business of participating NIHR programmes









- The Public's Health
- Ageing / Dementia
- Non-communicable Diseases
- Infections
- Rare Diseases
- Gender in Academic Medicine
- Our R&D response

Annual Report of the Chief Medical Officer, Volume 1, 2011



November 2012

	Prevalence	Cost to NHS	Cost to wider society	Impact on health
Tobacco	80,000 deaths p.a 20% Adults smoke	£2.7bn per year 5% of hospital admissions for over 35s	£14bn per year	Deaths from smoking-related diseases are mainly from cancer, heart disease or respiratory disease. Smoking can also cause non-life threatening diseases that can significantly reduce well-being, including blindness and male impotence.
Obesity	1 in 3 adults are overweight or obese In 2011, 61.5% of adults (aged 16 or over) and 30% of children (aged 2 to 10) in England were either overweight or obese	£5.1 bn per year	£16bn per year in 2007,	Obesity is a leading cause of serious diseases such as type 2 diabetes, hear disease and cancer. Risks for other diseases, including angina, gall bladder diseases, liver disease, ovarian cancer, osteoarthritis and stroke, are also raised.
Alcohol	15,000 deaths p.a 9 million people say they drink above the guidelines	New estimates show that alcohol misuse costs the NHS £3.5 billion every year There were 1.2 million alcohol- related hospital admissions in 2010/11	7.3bn per year due to lost productivity £11 bn per year due to crime costs	Drinking, especially above the lower- risk guidelines, can lead to a range of conditions, including cancer, stroke, liver and heart disease
Drugs	Nearly 205,000 people (adults) received treatment in 2010/11	The Pooled Treatment Budget (PTB) for drug treatment was £406 million in 2010/11, local areas also contribute further funding from mainstream PCT and Local Authority funding.	£15.4bn per year	Misuse of drugs is a key cause of societal harm, including crime, family breakdown and poverty. It undermines community cohesion and excludes drug users from society.
Physical Activity	Over 27m (2 thirds) adults in England are not meeting the Chief Medical Officer's physical activity recommendations	£1.6 bn per year as a result of inactivity	£5.5bn due to sickness absence £1bn from premature death	People who are physically active reduce their risk of developing major chronic diseases – such as coronary heart disease, stroke and type 2 diabetes – by up to 50%, and the risk o premature death by about 20–30%.